STAT+: Will Makary’s FDA voucher program survive?

STAT PlusNewsletterThe Readout Will Makary’s FDA voucher program survive? RevMed’s cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news Manage alerts for this article Email this article Share this article By Meghana KeshavanJune 5, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Even though RevMed’s experimental pancreatic cancer drug, daraxonrasib, hasn’t yet achieved approval, it is available through an expanded access program. But that doesn’t mean getting it is easy.Advertisement Also, the FDA’s voucher program spearheaded by erstwhile chief Marty Makary could be in for a makeover. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Politics June 4, 2026 STAT Plus: Drug companies, patient groups urge FDA to pause commissioner’s voucher program Pharma June 4, 2026 STAT Plus: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial Advertisement The Readout June 4, 2026 STAT Plus: AI titans push Congress for DNA safeguards Adam's Biotech Scorecard June 4, 2026 STAT Plus: Does Revolution Medicines’ pancreatic cancer drug have even greater potential? First Opinion June 4, 2026 Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story Subscriber Picks